Skip to content

Study · Randomized controlled trial · 2017

4 results

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH

Diabetes research and clinical practice27 Dec 2016Cited by 15 (Europe PMC)

PMID28086201 (opens in a new tab)DOI10.1016/j.diabres.2016.12.011 (opens in a new tab)PepBankPUB-28086201
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, 12 weeks of liraglutide did not affect postprandial haemodynamics compared with placebo.

    In plain wordsIn overweight adults with type 2 diabetes, liraglutide did not change blood pressure and blood flow after a meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changePostprandial haemodynamics
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Twelve-week liraglutide-treatment did not affect postprandial haemodynamics
    1 context sentence
    Summary · context
    57 patients with type 2 diabetes (mean±SD age 62.8±6.9years; BMI 31.8±4.1kg/m2; HbA1c 7.3±0.6%) were included in an acute (exenatide- or placebo-infusion) and 12-week (liraglutide, sitagliptin or placebo) randomised, placebo-controlled, double-blind trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, liraglutide did not affect sympathetic nervous system activity.

    In plain wordsIn overweight adults with type 2 diabetes, liraglutide did not change nervous system activity linked to the heart.

    Peptide
    Liraglutide
    Outcome
    No significant changeSympathetic nervous system activity
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Neither liraglutide nor sitagliptin affected SNS-activity or augmentation index
    1 context sentence
    Summary · context
    57 patients with type 2 diabetes (mean±SD age 62.8±6.9years; BMI 31.8±4.1kg/m2; HbA1c 7.3±0.6%) were included in an acute (exenatide- or placebo-infusion) and 12-week (liraglutide, sitagliptin or placebo) randomised, placebo-controlled, double-blind trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, liraglutide did not affect the augmentation index, a measure of vascular stiffness.

    In plain wordsIn overweight adults with type 2 diabetes, liraglutide did not change a measure of blood vessel stiffness.

    Peptide
    Liraglutide
    Outcome
    No significant changeAugmentation index
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Neither liraglutide nor sitagliptin affected SNS-activity or augmentation index
    1 context sentence
    Summary · context
    57 patients with type 2 diabetes (mean±SD age 62.8±6.9years; BMI 31.8±4.1kg/m2; HbA1c 7.3±0.6%) were included in an acute (exenatide- or placebo-infusion) and 12-week (liraglutide, sitagliptin or placebo) randomised, placebo-controlled, double-blind trial.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, all treatments, liraglutide included, significantly lowered postprandial glucose.

    In plain wordsIn overweight adults with type 2 diabetes, every treatment, liraglutide included, lowered blood sugar after a meal.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    All treatments significantly lowered postprandial glucose levels.
    1 context sentence
    Summary · context
    57 patients with type 2 diabetes (mean±SD age 62.8±6.9years; BMI 31.8±4.1kg/m2; HbA1c 7.3±0.6%) were included in an acute (exenatide- or placebo-infusion) and 12-week (liraglutide, sitagliptin or placebo) randomised, placebo-controlled, double-blind trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.